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CONTROVERSIES IN CARDIOTHORACIC SURGERYAre randomized trials the best way to judge the efficacy of surgical
procedures?Timothy J. Gardner, MDThoracic surgery is nearing its first century anniversary as
a unique medical specialty. In addition, the year 2010 marks
the 93rd anniversary of the founding of the American Asso-
ciation for Thoracic Surgery. What a century this has been
for thoracic surgery! We have witnessed previously unimag-
inable accomplishments in the surgical treatment of diseases
of the lung, esophagus, and heart. In the early part of the last
century, surgery for infectious complications of the chest
was common. Lung surgery for infection and cancer was
next to develop as controlled ventilation was mastered. Car-
diac surgery evolved dramatically from relatively simple
‘‘closed chest’’ procedures for congenital heart defects in
the middle years of the last century. After the refinement
of cardiopulmonary bypass 50 years ago, the range and num-
bers of cardiac surgical procedures exploded. As we reflect
on the current success of our specialty with its broad scope
of formidable surgical capabilities, we should challenge our-
selves to ask to what extent thoracic surgery has matured as
a scientific endeavor and a highly successful clinical spe-
cialty. Some have questioned the specialty’s commitment
to pursuing evidence-based surgical care. Are we committed
only to those surgical procedures that can be scientifically
validated to be effective? It is in this context we should
pose the question of whether ‘‘randomized controlled clini-
cal trials are the best way to judge the efficacy of surgical
operations.’’ There is an important stipulation to make, how-
ever, when discussing the importance of randomized trials to
determine the appropriateness of any surgical procedure.
Despite a commitment to the practice of evidence-based
medicine and operating only when we are confident about
the long-term consequences of the surgery, we must ac-
knowledge the critical role of surgical innovation, technical
development, and iterative refinements of surgical proce-
dures. The remarkable heritage of our specialty has been
the development of new, increasingly complex and highly
effective surgical procedures. Over this past century, tho-
racic surgeons have developed an awesome array of opera-
tions that have treated and cured millions of patients.
Along with these innovations and developments, however,
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Ensuring that our surgical procedures are effective and nec-
essary is the rationale and justification for conducting
randomized surgical trials.
EVIDENCE-BASED SURGERY?
How is evidence of safety and efficacy generated for sur-
gical operations? Consistent with the innovative history of
surgical therapy, case reports have been the usual first-line
method of dissemination of surgical results. Subsequent
single-center or single-surgeon reports of case series add
supportive but only limited evidence.1 Although many land-
mark surgical innovations have been reported for the first
time as case reports or small case series, these initial case se-
ries may be inadequate to demonstrate clear evidence of ef-
ficacy. Readily acknowledged limitations of such case series
include patient selection bias, possible lack of general appli-
cability when limited to procedures done by a single opera-
tor, and often an inadequate length and degree of follow-up
assessment to generate confidence in the reported outcome.
Reports by experienced and trusted surgeons create excite-
ment and frequently generate additional case series and tech-
nical refinements by other surgeons. Although this is the
usual pathway in the evolution of a new operation, the
history of thoracic surgery is replete with case reports and
surgical series of unsuccessful, unsafe, or ill-advised proce-
dures. This trial-and-error approach may be appropriate and
even necessary in the developmental stage of a new surgical
procedure. When a new operation is reported to be safe and
effective by several surgeons at more than one site, and the
new procedure is being considered for wide adoption, there
should be sufficient interest in the new operation to conduct
an observational study that involves some standardization of
the procedure and an attempt to involve multiple surgeons at
a variety of centers. This important next step to provide sup-
portive outcomes data to the anecdotal evidence of efficacy
derived from case series is, unfortunately, rarely done. Even
less common is the prospective, multicenter randomized trial
that is widely acknowledged as the standard way to develop
the appropriate evidence basis for any new therapy, includ-
ing procedural therapies. Despite all of the formidable chal-
lenges and obstacles inherent in performing randomized
surgical trials, such properly conducted studies are and
will remain the gold standard for judging safety and thera-
peutic efficacy.
As specific surgical procedures are widely adopted and of-
fered to patients, there is the understandable expectation by
those patients, their referring physicians, and the public thatrdiovascular Surgery c Volume 140, Number 4 739
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lished and can be performed safely by multiple surgeons at
many different sites. Desperately ill patients may be willing
to submit to a new surgical procedure when the operation is
offered as a last resort. A surgeon may be willing to under-
take an innovative procedure for an urgent indication when
he or she is reasonably confident of his or her surgical and
clinical abilities to safely perform the operation. It goes with-
out saying, however, that surgeons have the broader respon-
sibility to understand the full implications and consequences
of the procedures they are performing. In addition, despite
the traditional confidence in which surgeons are held by
other physicians and prospective patients, public reporting
of surgical outcomes is increasingly expected, if not de-
manded. Asking surgeons for clear evidence of efficacy
can be expected to be raised more often in the future, not
just by individual patients but by insurers, other providers,
and public health policy makers. In the context of health
care system reform in the United States, the use of compar-
ative effectiveness of medical therapy is being discussed
broadly and has become a mandate in the recent federal
health care legislation. Although health policy experts stress
that comparative effectiveness is a broader concept than sim-
ple ‘‘cost-effectiveness,’’ major invasive and expensive
therapies will be challenged for appropriateness on the basis
of results and costs. Furthermore, the evolution of less inva-
sive therapies that compete with or replace established and
traditional surgical procedures, including percutaneous
and endovascular interventions being performed by non-
thoracic surgeons, will mandate that we participate in com-
parative effectiveness analyses.Well-conducted randomized
trials will go a long way to establishing the evidence basis for
the effectiveness of many commonly performed and impor-
tant thoracic surgical operations.
EQUIPOISE: WHAT IS IT?
A common definition of equipoise when used in the con-
text ofmedical therapy is as follows: Equipoise defines a state
of uncertainty regarding the comparativemerits of 2 different
treatment options. It is little wonder that few surgeons are fa-
miliar with this terminology that was introduced in the con-
text of clinical trials by Benjamin Freedman, a medical
ethicist fromMcGill University, in theNew England Journal
of Medicine in 1987.2 Freedman’s article is titled ‘‘Equipoise
and the Ethics of Clinical Research.’’ He argues that each
clinical trial should begin with an honest null hypothesis, in-
dicating that the clinical investigator is in a state of genuine
uncertainty regarding the merits of a new treatment com-
pared with an established or accepted treatment. Freedman
contends that a physician who knows that one treatment is
superior to another cannot recommendparticipation in a com-
parative trial. On the other hand, he describes the concept of
‘‘clinical equipoise,’’ which represents genuine uncertainty
within the expert medical community, allowing for the indi-740 The Journal of Thoracic and Cardiovascular Surgvidual who may have some degree of bias about one treat-
ment versus the other to ethically participate in the trial.
Surgeons rarely admit to being in doubt about a proposed
operation. Uncertainty about a proposed operation is not
a comfortable position for surgeons. Patients, especially
those who are about to undergo a major operation with
short-term mortality risk, do not expect to detect uncertainty
about the effectiveness or safety of an operation from their
surgeon. It is one thing to be told that a new drug that has
been shown to be safe in preliminary trials may afford added
therapeutic benefit compared with an established medica-
tion; it is more challenging to offer a patient randomization
in a surgical trial with nothing more than a possibility that
a new surgical procedure may provide some potential bene-
fits compared with the established surgical approach. Pa-
tients, families, and referring physicians often become
uncomfortable when their surgeon suggests that he or she
is uncertain about which course of treatment to recommend.
On the other hand, skilled and committed clinical investiga-
tors have been highly successful in reassuring anxious pa-
tients that comparative clinical studies, especially trials
investigating new options for cancer therapies, may afford
the possibility of even more successful treatment than that
afforded by the established therapy.
This dilemma that is created by the surgeon appearing to
be uncertain and indecisive demonstrates how challenging it
is for many surgeons to admit that there is uncertainty about
the effectiveness of our procedures. We are expected to be
knowledgeable and decisive. Our work demands that we
be certain about our skills. We are expected to function in
an authoritative manner. After all, we are the captain of
the ship, and even others on the surgical team are uncomfort-
able when we are or appear indecisive. Equipoise seems to
be an oxymoron for an established surgeon. We would not
be undertaking a major operation with a mortality risk for
the patient unless we were certain of what we were propos-
ing to do.
Finally, there is the challenge related to the pride of own-
ership for many surgeons, in particular, those innovators
who have developed and championed new procedures for
treating a disease or life-threatening condition. Surgeons
with proprietary interests in devices are understandably con-
flicted. Those surgeons have worked hard to master a diffi-
cult procedure and may be resistant to consider engaging
in a trial comparing a safe and comfortable technique with
another potentially better operation. These are just some of
the explanations for the unwillingness of some surgeons to
achieve the state of equipoise that is required to convinc-
ingly participate in truly randomized clinical trials. Thoracic
surgeons as a specialty group have not demonstrated much
inclination to embrace the notion of equipoise.We are taught
to be thorough and scientific in our evaluation of clinical
data and decisive in our choice of therapeutic options. Ex-
pressions of doubt, inconsistency, and indecision are clinicalery c October 2010
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being examined by certifying boards, or rewarded with addi-
tional patient referrals when interacting with physicians. The
irony of this situation is that the demand for targeted and
quick decisions, even when meant to be based on evidence,
often results in poorly informed clinical actions, including
the choice of surgical procedures, the consequences of
which are poorly understood. Determining the evidence
base for our clinical and surgical decisions can be effectively
accomplished by the appropriate use of well-designed and
executed randomized clinical trials.
WHAT CHARACTERIZES AWELL-DESIGNED
AND EXECUTED SURGICAL TRIAL?
The most common design type for surgical trials is the in-
dividually randomized, 2-group, parallel trial. The term
‘‘controlled’’ is redundant in most instances and is used sim-
ply to indicate that a control treatment group that receives no
treatment or standard treatment is being compared with
a new treatment. Trials that compare a major surgical oper-
ation with a non-operative control arm, although important
and quite useful, have been challenging in terms of recruit-
ment. Even when the surgical procedure under consideration
holds substantial promise of benefit based on preliminary
case reports, it can be difficult to convince patients to submit
to randomization into a surgical treatment arm versus med-
ical treatment alone, when the operation has mortality and
major morbidity risks. Nonetheless, there have been impor-
tant and successful randomized surgical trials, such as the
Coronary Artery Surgery Study3 and the National Emphy-
sema Treatment Trial,4 that have compared a surgical treat-
ment patient group with a control group that received
medical treatment only. It has been generally easier to enroll
patients into randomized surgical trials when patients in both
parallel arms of the study are undergoing an operative
procedure. Two recent examples of large multicenter ran-
domized surgical trials comparing different operative proce-
dures are the VA Randomized On/Off Bypass Trial5 and the
Coronary Bypass Surgery with or without Surgical Ventric-
ular Reconstruction Trial.6
All of these trials share important characteristics of well-
conducted randomized trials. Many surgeons at multiple
sites participated, creating a ‘‘real-world’’ context and miti-
gating the influence of surgeons with exceptional technical
experience or proficiency. The requirement for adequate
statistical power was met in that the trials had adequate
projected sample sizes and actual patient enrollment to
achieve statistical confidence that the outcomes were not a re-
sult of chance. Inclusion and exclusion criteria were well
defined, ensuring that patients in each treatment arm were
comparable. Strictly enforced allocation into each arm re-
sulted in true randomization and eliminated the possibility
of selection bias. Patients were followed according to the ini-
tial treatment allocation regardless of whether the patientThe Journal of Thoracic and Caactually received the allocated intervention, again mitigating
the influence of post-randomization selection bias. Prede-
fined primary and secondary outcomes were assessed.
Both early and late outcomes are observed. It is noteworthy
that only late outcomes assessment in the Bypass Angio-
plasty Revascularization Investigation Trial that compared
percutaneous coronary balloon angioplasty with coronary
artery bypass grafting demonstrated a difference in survival
among diabetic patients, favoring those who had undergone
surgery.7
An important aspect of a well-executed clinical trial in-
cludes appropriate documentation and reporting of the trial
in a biomedical journal. Editors of many medical journals,
but few surgical journals, have adopted reporting standards
using the Consolidated Standards for Reporting of Trials
checklist to ensure inclusion of all critical information re-
quired for interpretation of trial results.8 Compliance with
these standards confers greater credibility to the reported
trial and will facilitate use of the trial in future high-
quality meta-analyses. Another useful addition to a well-
conducted clinical trial is a registry of screened or eligible
patients. Because a relatively small percentage of screened
patients are actually enrolled in a randomized trial, it can
be informative to assess the reasons for ineligibility or exclu-
sion from the trial.
MOVING FORWARD IN DEFENSE OF
RANDOMIZED SURGICALTRIALS
As most surgeons readily acknowledge, and as com-
mented on above, randomized surgical trials are challenging
to conduct. In some ways, randomization of a surgical proce-
dure goes against some of themost respected traditions of our
specialty.We are taught fromour earliest days as surgical res-
idents to determine specific indications for specific opera-
tions and to decisively choose the right operation for
a patient in need of surgery. We continue to look to senior
surgeons and experts for guidance about what operation is
most appropriate for which patient. Our respect for this sur-
gical authority is deeply embedded in our thinking, as is ev-
ident from our dependence on presentations at specialty
meetings and publications in medical journals for determin-
ing our choice of operations and treatment plans. The individ-
ual surgeon’s technical skills and confidence also influence
his or her choice of an appropriate operation. Asking a sur-
geon to participate in a randomized trial in which an unfamil-
iar procedure may be mandated is not comfortable for the
surgeon or safe for the patient, nor would participation by
that surgeon be ethical. The understandable bias that derives
from one’s own surgical experience or has resulted from the
influence of respected colleagues challenges the degree of
equipoise that is required of a surgical investigator. Equally
formidable are the practical obstacles to performing clinical
trials today, including the lack of available funding, absence
of clinical research infrastructure in many surgical programs,rdiovascular Surgery c Volume 140, Number 4 741
Controversies in Cardiothoracic Surgery Gardnerand human subject research regulations that have become in-
creasingly burdensome.
On the other hand, the medical profession and, in particu-
lar, surgeons are being challenged to validate our proposed
medical treatments and procedures. We will be increasingly
required to demonstrate and document the safety and effec-
tiveness of our surgical treatments. Randomized trials are
at the peak of the evidence tree and are the best way to pro-
vide that expected evidence. Thoracic surgery’s own Prac-
tice Guidelines recognize that data derived from multiple
randomized clinical trials allow us to make Level A treat-
ment recommendations. Although Level B evidence is
obtained from a single randomized trial or from nonrandom-
ized reports, most choices of treatment and surgical options
today are only at evidence Level C, that is, evidence that
is based on consensus expert opinion. This is the same
‘‘evidence’’ that relies on surgeons’ experiences and case re-
ports. The likelihood, if not the prediction, of erroneous treat-
ment choices that are based on such expert opinion is
substantial. Today’s expert is tomorrow’s fool dunce, duped
not from a lack of effort or good intent, but from bias, limited
experience, misinterpretation, or lack of awareness or
acknowledgement of other treatment options. As mature742 The Journal of Thoracic and Cardiovascular Surgand respected specialists, thoracic surgeons must accept
the challenge of participation, whenever feasible, in well-
designed randomized trials. Our credibility as clinical
scientists demands our leadership in such efforts and broad
participation by thoracic surgeons.References
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